Author Guidelines

For additional tools visit Author Services – a suite of online tools for Wiley Online Library journal authors, featuring Article Tracking, e-mail Publication Alerts, and more.

Author Guidelines

HEPATOLOGY publishes original research on the biology and diseases of the liver in both humans and experimental models.

Manuscripts should be sent with a cover letter to:
Michael H. Nathanson, M.D., Ph.D.
1001 North Fairfax Street, Ste. 400
Alexandria, VA 22314-1503
Telephone: 703-299-9766
Fax: 703-299-9676
To submit your manuscript electronically and for complete instructions on how to do so, go to

Types of Manuscripts

The Editors will consider and publish the following:

Manuscripts describing original research must be no longer than 6,000 words (including references), abstract of 275 words, no more than 50 references, and a title with no more than 120 characters (excluding spaces). Please include all relevant portions of the Methods section in the main manuscript. See Submission elements below. No more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit additional methodological details, nonessential figures or portions of your manuscript as supplementary material for online publication only.

Rapid Communications describing original research that may be groundbreaking, time-sensitive, and impactful are eligible for a rapid, thorough, and comprehensive review and publication process. Rapid Communications must be no longer than 6,000 words (including references), abstract of 275 words, no more than 50 references, and a title with no more than 120 characters (excluding spaces). No more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit nonessential figures or portions of your manuscript as supplementary material for online publication only. Only one revised submission of each manuscript will be reviewed after an initial submission is reviewed in the rapid review process, and the revised manuscript must be submitted within one week.

Reviews of both basic and clinical topics should be no longer than 6,000 words (including references). The reference list need not be exhaustive. While most reviews are invited by the Editors, authors interested in contributing reviews are requested to first contact the Editor or one of the Associate Editors with an outline of the proposed article.

Letters to the Editor may be subjected to peer review and undergo editing for clarity and brevity, and should be no longer than 500 words (including references) and include no more than 5 references and one figure.

Editorials are invited by the Editor or Associate Editors and should be no longer than 1,500 words (including references) and include no more than one figure or table and 10 references.

HEPATOLOGY Elsewhere should be no longer than 1,500 words (including references) and include no more than 8 references and one figure or table and are invited by an Associate Editor. The commentary should begin with a one paragraph summary of the article being discussed. Suggestions for this type of manuscript should be made to the Editor or an Associate Editor (see the Editorial Board for appropriate Associate Editors).

Clinical Observations in HEPATOLOGY submissions are intended to be outstanding case-based contributions which describe a unique presentation, novel observation, or cutting edge approach to management of a liver disease. The format should not include an abstract. It should include a brief introduction, presentation of the case (or case series), and discussion. The maximum length is 750 words, including the summary and references. There is a maximum of 2 figures or tables, and 5 references.

Observations in Hepatotoxicity are published quarterly in HEPATOLOGY in place of Clinical Observations. Material published in this section is selected from submissions to Clinical Observations and are intended to be case-based novel presentations or mechanistic insights of drug or herbal and dietary supplement induced hepatotoxicity. The format should include a brief introduction, presentation of the case (up to three), and discussion. The authors must ensure that the case contains elements needed to fully assess causality, as described elsewhere. (Agarwal VK, et al. Clin Gastroenterol Hepatol. 2010;8:463-470). The maximum word length is 750 words, including the summary and references. There must be no more than 3 authors. There is a maximum of two figures or tables and 5 references.

Special Articles are on a variety of topics and may include AASLD practice guidelines, in-depth scientific reviews, meeting reports, and comments on social policy. It's recommended that the length of each article is kept within the 6,000 words (including references) but it's also decided by the Editor on a case-by-case basis.

Concise Reviews of both basic and clinical topics should be no longer than 3,000 words (including references). The reference list need not be exhaustive. While most concise reviews are invited by the Editors, authors interested in contributing concise reviews are requested to first contact the Editor or one of the Associate Editors with an outline of the proposed article. The topics described in concise reviews should be more focused than the topics described in regular reviews.

Master’s Perspectives are invited by the Editors and focus on major leaders in the field of hepatology who can look back on their careers and tell us about their life story and illustrate how careers in our specialty have evolved. These should be no longer than 2,500 words with two figures or tables and no references.

Introduction of the AASLD President is invited by the Editors and should be no longer than 2,500 words with one figure or table and no references.

Obituaries are invited by the Editors and should not include references.

Manuscripts that exceed the word limits listed above will be returned to the authors for shortening without a full review. Manuscripts that are redundant or contain extraneous material will be returned after a full review for shortening even if otherwise acceptable.

If the concept and idea for this study originated with anyone other than the senior or corresponding authors, please provide details in the manuscript cover letter. Specifically state in the cover letter whose idea the study was, especially if the idea came from someone who is not an author. If any of the authors were provided financial incentives or honoraria for their work on this manuscript, please provide details in the manuscript cover letter.

Submission Elements

Submissions must include the following:

  • Complete manuscript (title page, author information, abstract, and text) as one Microsoft Word document
  • Tables submitted separately in one Microsoft Word document
  • Figures submitted separately in TIFF format with a resolution of 300 dpi (dots per inch)
  • No more than 8 figures and tables, with a maximum of 6 panels per figure. We encourage you to submit non-essential figures or portions of your manuscript as supplementary material for online publication only
  • Any material that could constitute prior or concurrent publication of similar data by any of the authors, including symposium proceedings, book chapters, invited papers, and the like
  • The names of reviewers whose expertise qualifies them to review the work
  • A description of any commercial affiliation or consultancy of an author that could be construed as a conflict of interest (this information will be kept confidential unless the Editor recommends disclosure in a footnote if an appearance of a conflict is perceived)
  • An author agreement signed by every contributing author. It is assumed, however, that the corresponding author speaks for his or her coauthors and certifies that all listed authors participated meaningfully in the study and that they have seen and approved the final manuscript.
  • Editorial formatting (use of italics, superscripts, Greek letter, etc.) should be consistent. Typographical formatting (column widths, type styles, etc.) should not be used. Text should be flush left; paragraphs should not be indented and should be separated by two hard returns. Do not use hard returns within paragraphs. Do not use the program's indenting or margin-setting features; these will be added during typesetting.
  • Submissions may include the names of any reviewers the authors wish to exclude along with the reason for exclusion for the Editors to consider.
  • Requests to exclude an Associate Editor can only be considered if a clear conflict of interest is explained in the cover letter.

Manuscript Organization

All elements of a manuscript should be double-spaced, and all pages must be numbered in the upper right corner, starting with the title page. Manuscripts describing original research should contain, in this order, the following elements:

Title Page
Title. No more than 120 characters, not including spaces between words. The use of acronyms and abbreviations should be avoided. The species used for work with experimental animals must be indicated in the title.

Author Names. The full name, e-mail, and institutional affiliation of all authors must be included. In a multi-authored work involving more than a single institution, indicate individual affiliation by means of a superscript Arabic number. Indicate a change of address similarly.

Keywords. Five keywords that do not appear in the title itself.

Footnote Page
Contact Information. Name, address, telephone number, fax number, and e-mail address for the corresponding author.

List of Abbreviations. Include the expansions and list in the order of their mention in the paper.

Financial Support. List grants and other financial support.

Write as continuous text organized as background and rationale for the study, main results, and conclusions. Acronyms and abbreviations must be defined in the abstract to allow the abstract to stand alone. Do not exceed 275 words. The last section should start with “Conclusion:

Introductory Statement
Do not include a heading. Provide the minimum background information that will orient the general reader.

Experimental Procedures
Provide a level of detail such that another investigator could repeat the work; for methods that are used without significant modification, citation of the original work will suffice.

Human Subjects. For reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.

Animal Experimentation. In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Manuscripts that use mice and other in vivo experimental models should include the following information:
• Sex and age of mice (or other in vivo experimental models) for all the experiments;
• The genetic background(s) of the mice or other experimental in vivo models;
• For transgenic or genetic mouse models, whether the controls were sibling littermates or were purchased separately (if purchased separately, were the animals cohoused to minimize potential microbiome effects);
• Specifics of the animal diet composition;
• Whether mice were fasted (and for how long) or not before a challenge or assessment is carried out;
• Type of bedding, caging system, and enrichment used for housing the mice; and
• If interventions were done, were they done during the light or dark cycle.

Genetic Sequence Data. In papers reporting a novel DNA or amino acid sequence, verify that the data have been or will be submitted either to GenBank or EMBL, and provide the accession number. This information need not accompany the initially submitted manuscript but must be available for inclusion in the final publication. Accession numbers appear as footnotes to the text or in the relevant figure legend. It is understood that authors publishing in HEPATOLOGY will make cloned DNA, hybridomas, mutant animals, and other resources available to qualified investigators. Raw data submitted with a manuscript may only be electronically published and available to HEPATOLOGY readers at the Journal’s Web site.

Manufacturers. Include the names and locations (city and state or country) of manufacturers when mentioning proprietary drugs, tools, instruments, software, etc.

Clinical Trials
Randomized controlled trials should be presented according to the CONSORT guidelines (JAMA 2001;285:1987-1991 or ). Authors must provide the CONSORT checklist (found at, under Instructions and Forms) with a diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. Manuscripts that fail to comply with CONSORT guidelines or do not include the CONSORT checklist at the time of submission will not be reviewed for publication. All clinical trials should be registered in order to be published in HEPATOLOGY.

All clinical trials should be registered in order to be published in HEPATOLOGY.

Results and Discussion
These two sections must be separate. Present the major findings of the study in graphic form if practicable. Do not illustrate minor details if their message is conveyed adequately by simple descriptive text. Mention all tables and figures. In the discussion, concisely present the implications of the new findings for the field as a whole, minimizing reiteration of the results, avoiding repetition of material in the introduction, and keeping a close focus on the specific topic of the paper.

Number references in the order cited as Arabic numerals in parentheses on the line. Only literature that is published or in press (with the name of the publication known) may be numbered and listed; abstracts and letters to the editor may be cited, but they must be less than 3 years old and identified as such. Refer to only in the text, in parentheses, other material (manuscripts submitted, unpublished data, personal communications, and the like) as in the following example: (Chercheur X, unpublished data). If the owner of the unpublished data or personal communication is not an author of the manuscript under review, a signed statement is required verifying the accuracy of the attributed information and agreement to its publication. Use Index Medicus as the style guide for references and other journal abbreviations. List all authors up to six, using six and “et al.” when the number is greater than six. For all listed citations with two or more authors who share first authorship, HEPATOLOGY stipulates those authors’ names to be in bold type. It is the authors’ responsibility to ensure that these names appear in bold in the reference section when submitting a manuscript. This allows giving due credit to joint first authors. Also, please include the phrase, “Author names in bold designate shared co-first authorship” at the end of the references section if you have citations that have joint first authors.

Journal Articles

1. Crawley AC, Brook DA, Muller VJ, Petersen BA, Isaas EL, BiekickiJ, King BM, et al. Enzyme replacement therapy in feline model of the Matroteaux-Lamysyndrome. J Clin Invest 1996;97:1864-1873.

2. Watson JD. The Double Helix. New York: Atheneum, 1968:1-6.

Book Chapters
3. Hofmann AF. The enterohepatic circulation of bile acids in health and disease.In: Sleisinger MH, Fordtran JS, eds. Gastrointestinal Disease. Volume 1. 5th ed. Philadelphia: Saunders, 1993:127-150.

Abstract or Article in a Supplement
4. Klin M, Kaplowitz N. Differential susceptibility of hepatocytes to TNF-induced apoptosis vs necrosis [Abstract]. HEPATOLOGY 1998;28(Suppl):310A.


Prepare tables on individual Word documents, double-spaced, and numbered consecutively with Arabic numerals in the order of their appearance in the text. Do not duplicate material presented in a figure. Large tables submitted with a manuscript may only be electronically published and available to HEPATOLOGY readers at the Journal’s Web site. Tables should read vertically when possible and should have headings for each column.

Figure Legends

Number with Arabic numerals in the order mentioned in the text. Provide a title (this should not appear on the figure itself) and sufficient explanation to render the figure intelligible without reference to the text. Explain all abbreviations and symbols. For any copyrighted material, indicate that permission has been obtained (see Permissions, below). Figure legends can be provided within the main text or on a separate Microsoft Word document.

Supporting Information

Additional supplementary materials that are intended for online publication only must be clearly labeled as such and included with the initial submission.

Other Manuscript Elements

Acknowledgment. Acknowledge personal assistance and providers of special reagents. Note that grant and other financial support is listed on the footnote page, not here.

Permissions. Direct quotations, tables, or illustrations taken from copyrighted material must be accompanied by written permission for their use from the publisher and the original author. A standard permission request form is included in this section. The permission is presented as a footnote or addition to the legend and must provide complete information as to source. Photographs of identifiable persons must be accompanied by a signed release that indicates informed consent.

Abbreviations. Standard abbreviations not requiring definition can be found in the AMA Manual of Style. Do not abbreviate otherwise unless a term is used more than five times in the manuscript. In this case, the abbreviation should be spelled out, in parentheses, in its first use in the text and also listed on the footnote page (see above). Abbreviations used in figures or tables should be defined in the legend. Express temperatures as degrees Celsius and other measurements in SI units.

Drug Names. Use generic names. The proprietary name may be mentioned in parentheses with the name and location (city and state or country) of the manufacturer.


All figures submitted for review need to be in TIFF (Tagged Image File Format) or EPS (Encapsulated Post-Script) format.

All figures (black and white or color) need to have a resolution of at least 300 DPI (dots per inch) at full size with no compression. Color figures should be in RGB color mode and black and white figures should be set to Grayscale color mode.

We recommend Adobe Photoshop for generating pixel-based graphics and either Adobe Illustrator or Macromedia’s Freehand for generating vector-based graphics. Black and white (B/W) line art is either pixel based (typically generated by scanning the image) or vector based (generated using a drawing program such as Freehand or Illustrator). Pixel-based artwork should be supplied in TIFF format and at a resolution of not less than 300 dots per square inch (dpi). Vector-based artwork should be supplied as EPS files. B/W halftones should be supplied in TIFF format. The halftone should be provided at the proper resolution. The finished resolution should be at least 300 dpi. Color artwork should be provided as an EPS or TIFF file. The finished resolution should be at least 300 dpi. Note that these file formats are not acceptable for printing: JPG, GIF, ONG, PCX, PNG, XBM, PDF, PPT, MS Word, Rar, and Excel. We recommend creating your graphics in Photoshop, Illustrator, or Freehand and importing them into your page applications as TIFFs with all fonts included. Do not scan figures as JPEGs and convert to TIFFs.

Some figures may be converted from PowerPoint format to TIFF format by following Instructions for converting PowerPoint format to TIFF below.

To ensure that your digital graphics are suitable for print purposes, please go to Rapid Inspector at This free, stand-alone software application will help you to inspect and verify illustrations right on your computer.

Instructions for converting PowerPoint format to TIFF

  • In PowerPoint, choose file and print.
  • Select PDF from the drop down menu.
  • Click on Properties and select the Adobe PDF Settings.
  • Select High Quality from the drop down menu.
  • Make sure the following boxes are checked: view Adobe PDF results, prompt for Adobe PDF filename, add document information, do not send fonts to “Adobe PDF”, and delete log files of successful jobs.
  • Click OK on the Adobe PDF Document Properties dialog box.
  • Click OK on the Print dialog box.
  • Save the file to your computer.
  • The PDF will automatically open in Adobe Acrobat. Look over your figure and make sure everything looks right.
  • If everything looks fine, follow these instructions:
  • Open your PDF in Adobe Photoshop.
  • In the Rasterize Generic PDF Format dialog box, change the resolution to the appropriate setting (300 Pixels/Inch for pictures).
  • Please note that your figures are set at full size and the Mode is set accordingly— Grayscale for black and white figures and RGB for color figures.
  • Make sure the Anti-aliased and Constrain Proportions boxes are checked. Click OK to open.
  • In the Layers Palette, click on the small triangle on the right to access the drop down menu (if the Layers Palette is not showing select the Windows menu and choose Layers).
  • Select Flatten Image.
  • Next, choose File and Save As.
  • Choose TIFF format from the drop down menu and click the Save button.
  • In the TIFF Options dialog box, choose none for the compression and IBM PC for the byte order.

Authors are charged for color figures, the cost being $500 for each page (whole or partial). Figures submitted in color for review will be published in color.
The publisher will send an invoice for color charges directly to the corresponding author.

Cover Photograph.
Authors with accepted manuscripts may submit artwork for consideration for the cover via email to The material may be different from the figures used in the article but should represent its content. Single slides or color photographs are preferred, and multiple examples may be submitted. Individual photographs should be trimmed to 21 × 28 cm (width × height) for production as is, and they should be accompanied by a four- to five-word caption and a two-sentence legend. Authors are not charged for a cover photograph.

Peer Review and Publishing

The Journal uses anonymous peer review in evaluating manuscripts for publication. The Editor can choose to Early Reject a manuscript without peer review if the manuscript is incomplete or unlikely to be accepted. The Editor allows a single resubmission only after the initial disposition. A manuscript requiring more than a single revision or returned beyond three months of the date of the initial decision will be considered a new submission.

Authors lacking facility with English syntax should seek the appropriate assistance prior to submitting their manuscript.

Copyright of all material published in HEPATOLOGY is vested in the American Association for the Study of Liver Diseases. In accordance with the Copyright Act of 1976, a Copyright Assignment form (which follows these guidelines) signed by all authors must accompany all manuscripts. Statements and opinions expressed in the articles and communications in HEPATOLOGY are those of the author(s) and not necessarily those of the Editor(s) or publisher, and the Editor(s) and publisher disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher guarantees, warrants, or endorses any product or service advertised in the Journal, nor do they guarantee any claim made by the manufacturer of such product or service.

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit:

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

Conflict of Interest

Please disclose all financial arrangements within the past two years, including consultancies, stock ownership, equity interest, patent-licensing agreements, research support, major honoraria, etc. you have with a company whose product figures prominently in the manuscript you are submitting, sending a letter to the editor, or providing an editorial. Please provide the same information for similar relationships with a company making a competing product to that which is featured in the manuscript. If the Editor finds that such activities raise the appearance of a conflict, he may recommend disclosure in a footnote. Otherwise, the information will remain confidential.